Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 15, 2025 07:14 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study

First patient in SXTP’s relapsing babesiosis study tested negative post-tafenoquine; FDA Breakthrough request filed, Type B meeting planned 2026.
August 13, 2025 16:14 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results

60 Degrees Pharma (Nasdaq: SXTP) Q2 2025: Supply issue cut revenue, profits rose from cash-pay sales; $1.97M cash extends runway to Mar 2026.
July 16, 2025 16:01 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering

60 Degrees closes $5M public offering with up to $5M more from short-term warrants; funds support working capital and infectious disease R&D.
July 15, 2025 09:10 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering

60 Degrees Pharma (SXTP) prices $5M public offering with potential $5M from warrant exercise; funds to support working capital and corporate purposes.
July 15, 2025 07:01 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion

60 Degrees sets human babesiosis TAM for ARAKODA at $245M annually, $1.1B total through 2035; NDA planned for 2026 pending trial data.
June 03, 2025 08:49 ET | Source: Sixty Degrees Pharmaceuticals

Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals

Insurance claims show U.S. babesiosis incidence may be 10x CDC estimates; 60 Degrees links chronic fatigue and plans 2026 NDA for tafenoquine treatment.
April 22, 2025 08:44 ET | Source: Sixty Degrees Pharmaceuticals

Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey

60 Degrees Pharma survey suggests babesiosis affects up to 3M Americans—vastly more than CDC data—and may underlie millions of chronic fatigue cases.
April 10, 2025 08:31 ET | Source: Sixty Degrees Pharmaceuticals

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

60 Degrees Pharma CEO Geoff Dow, PhD, will discuss babesiosis threats and therapies at the virtual Healing Lyme Summit, April 15–21
April 08, 2025 08:31 ET | Source: Sixty Degrees Pharmaceuticals

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

60 Degrees Pharma partners with Yale to develop tafenoquine for treating and preventing babesiosis, a severe tick-borne disease with limited treatments.
March 28, 2025 06:59 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Announces 2024 Annual Results

60 Degrees Pharmaceuticals (SXTP) reported 140% revenue growth in 2024, driven by Arakoda® sales. Clinical trials and market expansion efforts continue.